Discover SciSparc Ltd.'s significant legal victory in its February 2025 Form 6-K report, detailing a favorable settlement that enhances financial standing and operational commitments.
Explore SciSparc Ltd.'s Form 6-K report detailing a 180-day Nasdaq compliance extension. Key insights on regulatory challenges and company updates.
Discover SciSparc Ltd.'s January 2025 Form 6-K report detailing a key partnership with Clearmind Medicine and a new European patent application in psychedelic therapy.
SciSparc Ltd. announces the renewal of its clinical trial approval for autism research in children. Report includes crucial updates and is filed under Form 6-K.
Discover SciSparc Ltd.'s latest Form 6-K filed on Dec 26, 2024, detailing a $13M vehicle delivery deal with AutoMax. Key corporate developments and regulatory insights included.
Explore SciSparc Ltd.'s December 2024 Form 6-K report detailing the strategic spin-off of its pharmaceutical portfolio, signed by CEO Oz Adler. Essential for investors!